{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:03:53Z","timestamp":1788264233537,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T00:00:00Z","timestamp":1384992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12185-013-1465-y","type":"journal-article","created":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T08:19:03Z","timestamp":1384935543000},"page":"69-78","source":"Crossref","is-referenced-by-count":19,"title":["High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis"],"prefix":"10.1007","volume":"99","author":[{"given":"Lin","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-kai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-heng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-liang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-gong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,21]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"1465_CR2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"J Anderson","year":"1998","unstructured":"Anderson J, Armitage J, Weisenburger D. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol. 1998;9:717\u201320.","journal-title":"Ann Oncol."},{"key":"1465_CR3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.3.CO;2-8","volume":"83","author":"YH Ko","year":"1998","unstructured":"Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Cancer. 1998;83:806\u201312.","journal-title":"Cancer"},{"key":"1465_CR4","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/cncr.20531","volume":"101","author":"F Morabito","year":"2004","unstructured":"Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer. 2004;101:1601\u20138.","journal-title":"Cancer"},{"key":"1465_CR5","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Bri\u00e8re J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood. 1998;92:76\u201382.","journal-title":"Blood"},{"key":"1465_CR6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20135.","journal-title":"N Engl J Med"},{"key":"1465_CR7","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","volume":"18","author":"C Haioun","year":"2000","unstructured":"Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: final analysis of the prospective LNH87-2 protocol\u2013a groupe d\u2019Etude des lymphomes de l\u2019Adulte study. J Clin Oncol. 2000;18:3025\u201330.","journal-title":"J Clin Oncol"},{"key":"1465_CR8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","volume":"350","author":"N Milpied","year":"2004","unstructured":"Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287\u201395.","journal-title":"N Engl J Med"},{"key":"1465_CR9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","volume":"92","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, Lahuerta J, Arranz R, Sureda A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma. Haematologica. 2007;92:1067\u201374.","journal-title":"Haematologica"},{"key":"1465_CR10","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodriguez","year":"2003","unstructured":"Rodriguez J, Caballero MD, Gutierrez A, Mar\u00edn J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768\u201375.","journal-title":"Ann Oncol"},{"key":"1465_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T Kewalramani","year":"2006","unstructured":"Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134:202\u20137.","journal-title":"Br J Haematol"},{"key":"1465_CR12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","volume":"27","author":"AK Blystad","year":"2001","unstructured":"Blystad AK, Enblad G, Kval\u00f8y S, Berglund A, Delabie J, Holte H, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27:711\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1465_CR13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533\u20138.","journal-title":"Leukemia"},{"key":"1465_CR14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n A, Mar\u00edn J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79:32\u20138.","journal-title":"Eur J Haematol"},{"key":"1465_CR15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958\u201363.","journal-title":"Ann Oncol"},{"key":"1465_CR16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106\u201313.","journal-title":"J Clin Oncol"},{"key":"1465_CR17","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: nLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"1465_CR18","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008."},{"key":"1465_CR19","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: cotswolds meeting. J Clin Oncol. 1989;7:1630\u20136.","journal-title":"J Clin Oncol"},{"key":"1465_CR20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"1465_CR21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20139.","journal-title":"Blood"},{"key":"1465_CR22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"1465_CR23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","volume":"14","author":"AI Chen","year":"2008","unstructured":"Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14:741\u20137.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1465_CR24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n A, Mar\u00edn J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652\u20137.","journal-title":"Ann Oncol"},{"key":"1465_CR25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","volume":"17","author":"A Nademanee","year":"2011","unstructured":"Nademanee A, Palmer JM, Popplewell L, Tsai NC, Delioukina M, Gaal K, et al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. Biol Blood Marrow Transplant. 2011;17:1481\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1465_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"DH Yang","year":"2009","unstructured":"Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant. 2009;15:118\u201325.","journal-title":"Biol Blood Marrow Transplant."},{"key":"1465_CR27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","volume":"33","author":"E Jantunen","year":"2004","unstructured":"Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405\u201310.","journal-title":"Bone Marrow Transplant"},{"key":"1465_CR28","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","volume":"45","author":"M Jagasia","year":"2004","unstructured":"Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, Shyr Y, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma. 2004;45:2261\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1465_CR29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"1465_CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","volume":"40","author":"SD Smith","year":"2007","unstructured":"Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant. 2007;40:239\u201343.","journal-title":"Bone Marrow Transplant"},{"key":"1465_CR31","first-page":"218","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:218\u201324.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1465_CR32","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","volume":"14","author":"AD Zelenetz","year":"2003","unstructured":"Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2003;14(Suppl 1):i5\u201310.","journal-title":"Ann Oncol"},{"key":"1465_CR33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"1465_CR34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol. 2006;58:35\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1465_CR35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","volume":"60","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60:129\u201334.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1465_CR36","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316\u201323.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-013-1465-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1465-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T17:27:26Z","timestamp":1564853246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-013-1465-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,21]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1465-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,21]]}}}